De Rosa Nicoletta, Lavitola Giada, Giampaolino Pierluigi, Morra Ilaria, Nappi Carmine, Bifulco Giuseppe
Department of Obstetrics, Gynecology, and Urology, University of Naples "Federico II", Naples, Italy.
Department of Public Health, University of Naples "Federico II", Naples, Italy.
Biomed Res Int. 2017;2017:7513610. doi: 10.1155/2017/7513610. Epub 2017 Jul 11.
Cervical cancer (CC) treatments impact quality of life (QoL) and sexual function (SF) of survivors. Treatment options to reduce sexual dysfunction are limited. The aim of this study was to assess the effectiveness of ospemifene in CC survivors with clinical signs and symptoms of vulvovaginal atrophy (VVA) focusing on their QoL and SF.
Fifty-two patients with previous diagnosis of stage I-IIa CC suffering from VVA and treated with ospemifene were enrolled into a single arm prospective study. Patient underwent 6 months of therapy. At baseline and after 6 months all subjects performed Vaginal Health Index (VHI). The SF and QoL were measured by The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) and the Cervical Cancer Module (CXC-24).
After treatment a significant improvement of each parameter of VHI has been demonstrated. Global health status and emotional and social functioning scores improved significantly. On the contrary, general symptoms scales did not show significant difference from baseline data. Sexual activity, sexual vaginal functioning, body image, and sexual enjoyment scores increased significantly.
Ospemifene seems to be effective in decreasing the VVA symptoms in CC survivors.
宫颈癌（CC）治疗会影响幸存者的生活质量（QoL）和性功能（SF）。减少性功能障碍的治疗选择有限。本研究的目的是评估奥培米芬对有外阴阴道萎缩（VVA）临床体征和症状的CC幸存者的生活质量和性功能的有效性。
52例既往诊断为I-IIa期CC且患有VVA并接受奥培米芬治疗的患者纳入单臂前瞻性研究。患者接受6个月的治疗。在基线和6个月后，所有受试者均进行阴道健康指数（VHI）评估。性功能和生活质量通过欧洲癌症研究与治疗组织（EORTC）生活质量问卷（QLQ）和宫颈癌模块（CXC-24）进行测量。
治疗后，VHI的各项参数均有显著改善。总体健康状况以及情感和社会功能评分显著提高。相反，一般症状量表与基线数据相比无显著差异。性活动、阴道性功能、身体形象和性愉悦评分显著增加。
奥培米芬似乎对减轻CC幸存者的VVA症状有效。
